OR WAIT null SECS
The second phase of a $5.5-million expansion adds controlled-substance and controlled-temperature storage to Catalent clinical trials facility.
Catalent Pharma Solutions announced on May 17, 2018 the completion of the second phase of a $5.5-million expansion program at its Kansas City, MO facility, which increased the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
The expansion included a Drug Enforcement Administration Schedule I and II controlled substance vault; 3600-sq.-ft. of additional storage; controlled-temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations; a sampling room; and an emergency generator.
The 450,000-sq.-ft. facility provides development and analytical support through to packaging and distribution, the company reported in a press statement. Previously, the company announced expansions at clinical supply facilities in Philadelphia and Singapore.
Source: Catalent Pharma Solutions